Skip to main content


Fig. 1 | Breast Cancer Research

Fig. 1

From: Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer

Fig. 1

Consolidated Standards of Reporting Trials (CONSORT) diagram of the study population. In this study, 87 patients with human epidermal growth factor receptor 2-positive (HER2 pos) breast cancer were enrolled; all tumors were histologically confirmed as invasive breast cancer (IBC) with HER2 overexpression (3+ or 2+/fluorescence in situ hybridization (FISH)-positive). Cohorts are labeled (ag) for ease of comparison (of immune responses), and are referred to in Results. Time points at which blood was drawn are indicated (red callout boxes). Median follow up in the cohort treated with trastuzumab and chemotherapy (T + C) was 26 (IQR 16.5–31.0) months. pCR pathologic complete response, DCI type 1-polarized dendritic cell, Adj adjuvant, mo months

Back to article page